There are 2789 resources available
507TiP - PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Presenter: Joleen Hubbard
Session: ePoster Display
509TiP - REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Presenter: Elodie Klajer
Session: ePoster Display
511TiP - A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
Presenter: Dongsheng Zhang
Session: ePoster Display
521P - Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Presenter: Maria Vieito
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
524P - A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis
Presenter: Melissa Johnson
Session: ePoster Display
525P - Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Presenter: Meredith Mckean
Session: ePoster Display